Mirtazapin Orion (Mirtazapine)

Mirtazapine blocks presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine, and antagonizes postsynaptic 5‑HT2 and 5‑HT3 receptors. This dual action enhances serotonergic and noradrenergic neurotransmission while reducing certain serotonin‑related side effects, contributing to its antidepressant effect.

The specific dose is determined by the prescribing clinician based on the individual’s clinical condition, age, and response to therapy. Typical starting doses for adults often begin at a low level and may be adjusted upward, but exact dosing must be set by a qualified healthcare professional.

Safety data for mirtazapine in pregnancy and lactation are limited. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss risks with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapin Orion (mirtazapine) differs from selective serotonin reuptake inhibitors (SSRIs) by its dual noradrenergic and specific serotonergic activity, which often results in stronger sedative and appetite‑stimulating effects. This profile can be advantageous for patients with insomnia or weight loss, whereas SSRIs may have a lower risk of weight gain but can cause different side‑effects such as sexual dysfunction.

Mirtazapin Orion should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

The medication is supplied as oral tablets and is taken by mouth, usually once daily in the evening. It may be taken with or without food, but patients should follow the prescribing clinician’s instructions regarding timing and any dietary considerations.

Serious risks include the potential for suicidal thoughts or behavior, especially during the initial weeks of treatment, agranulocytosis or severe neutropenia, and serotonin syndrome when combined with other serotonergic drugs. Prompt medical attention is required if symptoms such as fever, sore throat, unusual bleeding, or signs of serotonin excess appear.

Mirtazapin Orion is contraindicated in patients with known hypersensitivity to mirtazapine or any of its excipients, and in those currently taking monoamine oxidase inhibitors (MAOIs) or who have used an MAOI within the past 14 days. Caution is also advised for individuals with severe hepatic impairment or uncontrolled epilepsy.